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Abstract
In HIV-1-infected individuals, there is often discordance between viremia in peripheral blood and viral load found
in the central nervous system (CNS). Although the viral burden is often lower in the CNS compartment than in the
plasma, neuroinflammation is present in most infected individuals, albeit attenuated by the current combined
antiretroviral therapy. The HIV-1-associated neurological complications are thought to result not only from direct
viral replication, but also from the subsequent neuroinflammatory processes. The eicosanoids - prostanoids and
leukotrienes - are known as potent inflammatory lipid mediators. They are often present in neuroinflammatory
diseases, notably HIV-1 infection. Their exact modulatory role in HIV-1 infection is, however, still poorly understood,
especially in the CNS compartment. Nonetheless, a handful of studies have provided evidence as to how these
lipid mediators can modulate HIV-1 infection. This review summarizes findings indicating how eicosanoids may
influence the progression of neuroAIDS.
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1. Background
HIV-1, which will be referred to as HIV throughout this
review, is widely known to cause devastating effects on
the immune system. Another important target is the
central nervous system (CNS), where macrophages and
microglial cells are the cell types predominantly infected
by HIV and responsible for virus propagation within the
CNS. The effect of various molecules that act as activa-
tors or suppressors in the modulation of HIV replication
dictates the viral load in the CNS. Although several such
molecules have been shown to be involved in the neuro-
pathogenesis of HIV infection and in the development
of HIV-associated dementia (HAD), the relative impor-
tance of several others remains elusive. Of these, eicosa-
noids - more precisely prostaglandins (PGs) and
leukotrienes (LTs) - have gained some attention during
recent years for their implication in HIV pathogenesis.
It is well documented that these lipid mediators perform
multiple functions in many biological systems, mainly in
inflammation and immunity. In the CNS, they play
important physiological roles, notably in the resolution
of inflammation and neuroprotective bioactivity. How-
ever, little is yet known on the complex relationships
between HIV and these soluble mediators in the CNS.
The current review will thus focus on the putative con-
tribution of eicosanoid derivatives, namely PGs and LTs,
to viral load and HIV-mediated neurological
complications.
2. HIV and the CNS
NeuroAIDS
It is now well accepted that HIV can cross the blood-
brain barrier (BBB) and infect the CNS early, during the
acute phase of the infection [1]. In the late stages of the
infection, a wide range of neuropathologic complications
are observed, such as neurotoxicity, neurodegeneration,
HIV encephalitis and associated neurocognitive deficits.
Neurological disorders are still strikingly prevalent,
reaching up to 50% of virus-infected individuals during
t h ec o u r s eo ft h ed i s e a s e[ 2 ] . Clinical manifestations
consist in a triad of neurological symptoms including
cognitive, motor and behavioural impairments, better
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active antiviral therapy (HAART) in 1995, most of the
infected population developed HAD at the late stage of
the disease. HAART has reduced this rate drastically.
H o w e v e r ,am o r es u b t l ef o r mo fC N Sd y s f u n c t i o n ,
known as minor cognitive motor disorder (MCMD)
continues to prevail in HIV-carrying persons. Symptoms
of MCMD include memory loss, as well as reduction of
cognitive and computational functions [3]. Thus, the
neurological manifestations and the inflammatory cas-
cade underlying the infection of the CNS by HIV are far
from being controlled by HAART. In fact, the relative
CNS penetration-effectiveness (CPE) scores for different
antiretroviral drugs used in HAART vary considerably,
from very poor (e.g. enfuvirtide and nelfinavir) to high
penetration (e.g. nevirapine and zidovudine) [4,5].
Nevertheless, it has been shown that the clinical out-
come of CNS impairments related to HIV infection does
not depend on the penetration efficacy of administered
antiretroviral drugs [4]. In some cases, HIV-associated
neurological disorders are actually worsened by the use
of antiretrovirals [6]. A recent study has notably shown
that maraviroc, a widely used CCR5 antagonist, actually
increases microglia proinflammatory activation by indu-
cing PGs synthesis, which may have the potential to
exacerbate neurological complications [7].
Discordance between plasma and CSF (cerebrospinal
fluid) viral loads in HIV-infected individuals has been
documented in the literature [8-10]. Interestingly,
HAART treatment seems to reduce the viral RNA con-
centrations more slowly in the CSF of some patients
than in their plasma [11]. As a corollary, some studies
have also shown that progression of HIV titers in the
CNS occurs more slowly than in the plasma of patients
with no neurological symptoms associated to HIV infec-
tion [12,13]. How the human body can control the viral
load in the CNS is still not fully understood. Moreover,
CNS viral strains may genetically differ over time from
those found in the peripheral blood [14]. In the light of
these observations, an involvement of cerebral innate
immunity is probable. Indeed, it has been shown in
non-human primate models that simian immunodefi-
ciency virus (SIV) replication is more efficiently con-
trolled in the CNS compartment than in the plasma
[15]. In these models, the innate immune response
seems to act as a key regulator of the viral burden in
the CNS [16].
Entry in and infection of the CNS by HIV
A wealth of knowledge has been published on the Tro-
jan horse model describing how the virus may enter the
CNS via infected leukocytes (mostly monocytes and/or
CD4
+ T lymphocytes) or via cell-independent pathways
[17-21]. This process is facilitated by a BBB disruption
brought about by circulating microbial endotoxins -
such as lipopolysaccharide found on Gram-negative bac-
teria - that enter the blood stream by translocation from
the gastrointestinal tract during the acute phase of HIV
infection [22-24] and by soluble HIV proteins such as
Tat, Nef and gp120 [25]. HIV is then considered to be
compartmentalized, on the one hand in the peripheral
immune system, and, on the other hand, in the CNS.
Once the virus enters the latter compartment, perivas-
cular macrophages and microglia are the main targets
for productive HIV infection. These cells can notably
act as stable reservoirs for HIV latency (reviewed in
[26]). Moreover, the infection and activation of these
cells leading to production of proinflammatory media-
tors in the CNS underlie the pathogenesis of neuroAIDS
[27]. Indeed, these inflammatory molecules do not only
impact the function of surrounding cells, but can also
alter tight junctions of the BBB, and enhance monocyte
recruitment [28]. Among these secreted factors are eico-
sanoids, the focus of this paper.
Microglia and HIV
Microglial cells are tissue macrophages that are ubiqui-
tously distributed in the CNS. They serve as neuropro-
tective cells and promote neurotrophic functions [29]. It
is now believed that microglia colonize the CNS from
two pools of myeloid cells. The first progenitors that
enter the embryonic and foetal CNS derive from hema-
topoietic cell precursors [30,31]. The second wave con-
sists in monocytes, predominantly expressing some
specific surface markers (i.e. CD11, CD14 and CD16),
that enter and colonize the CNS during the postnatal
period (infiltrating microglia) [32-34]. Microglial cells
play many important roles in homeostasis. They can act
as antigen-presenting cells, remove tissue debris follow-
ing a brain trauma, cross-talk with astrocytes in order to
regulate their proliferation, and produce cytokines and
chemokines, as well as other soluble factors known to
be involved in immunologic response, neuroinflamma-
tion and neurodegeneration [35-39].
As mentioned above, HIV once located within the
CNS will predominantly target microglial cells and peri-
vascular macrophages for productive infection. The
virus-encoded external envelope glycoprotein gp120 uti-
lizes different chemokine receptors and adhesion mole-
cules in combination with CD4 to establish an initial
contact with targets and eventually gains entry inside a
host cell. It is well documented that microglia are
mostly permissive to R5-tropic strains of HIV, which
enter via the CCR5 coreceptor [40-42]. However, some
data suggest that certain strains of HIV can also partly
utilize CCR3, therefore suggesting some degree of com-
plexity in the coreceptor usage by the virus on the sur-
face of microglia [42,43].
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been shown to activate microglial cells. Interestingly,
there is a better correlation between HAD and micro-
glial activation than with the viral load [44]. The gp120
envelope protein is one of many viral components
released in infected tissues. It has been shown to coloca-
lize with microglia in the brain of HIV-infected patients
[45]. Exposure of microglia to gp120 has been reported
to induce an activation response, including the release
of several molecules - such as TNF-a, IL-6, IL-1b,G M -
CSF and reactive oxygen species - that induce CNS
inflammation and neurotoxicity [19,46,47]. Another HIV
protein, namely Tat, can also be found in the CSF and
brain of HIV-infected individuals [48]. Treatment of
human microglial cells with exogenous Tat can trigger
the secretion of a broad range of proinflammatory mole-
cules (e.g. MCP-1, IL-8, MIP-1a, MIP-1b and RANTES)
[19].
Experiments aimed at defining the complex interac-
tions between HIV and human microglia have used pur-
ified primary microglial cells obtained from human
foetal brain tissues or brain specimens of patients
undergoing surgery. However, the limited quantity of
microglia that can be thus obtained has been a limiting
step. Interestingly, a novel model of primary human
microglia called human monocyte-derived microglia-like
cells (MDMi) has been developed [49]. The phenotype
of these cells resembles that of primary infiltrating
microglia found in the CNS, and they can support pro-
ductive HIV infection. This experimental model of
human microglia has been recently proven to be useful
for studying in vitro HIV infection in the CNS context
[50]. Alternatively, animal models using SIV have been
developed, which may prove useful for correlating the in
vitro studies with an in vivo approach [51].
Astrocytes and HIV
Astrocytes are the most abundant glial cells in the CNS.
They play several important roles, such as regulating the
external environment of neurons, participating in the
physical structuring of the brain, providing metabolites
to neurons, and maintaining the BBB integrity. Although
perivascular macrophages and microglia are the cells
that support productive virus infection in the CNS,
astrocytes are considered by many to support a
restricted virus replication. Indeed, only a subpopulation
of productively infected astrocytes can be detected in
vivo in HAD patients by sensitive techniques that detect
virus nucleic acids [52-55], although an extensive infec-
tion of these cells has also been reported in demented
infected individuals [56]. Nonetheless, much interest has
lately been focused on the infectability of astrocytes.
Their limited susceptibility to productive HIV infection
has been attributed to a pH-independent restriction at
the virus entry step [53,54] and an inhibition of the Rev
protein by a host restriction factor called Risp [57].
Latent HIV infection of astrocytes results in consider-
able changes in the host gene expression pattern [58,59].
Consequently, the secretome of infected astrocytes has a
major impact on neuronal cell death and BBB dysregula-
tion, and it correlates with HIV neuropathogenesis and
HAD severity [20,52]. Furthermore, recent findings sug-
gest that the infection of a small number of astrocytes is
sufficient to disrupt the BBB integrity by a gap junction-
dependent mechanism [60], thus reinforcing the pro-
posed important role for these few infected astrocytes in
the HIV-induced CNS damage.
Interestingly, cross-talk between HIV-infected astro-
cytes and microglia has important impacts on neuroin-
flammation and neurodegeneration processes seen in
the CNS. Indeed, HIV infection of astrocytes can
increase the neurotoxicity of infected microglia and
modulate viral growth and compensatory regulatory
pathways in these cells [61]. Therefore, the very low
number of virus-infected astrocytes can still play an
important role in the development of HIV-associated
encephalitis and neurological impairments.
3. Eicosanoids
Eicosanoids are signalling molecules that are generated
through an oxidative pathway from polyunsaturated
fatty acids, notably arachidonic acid (AA), an n-6 fatty
acid (or omega-6), and eicosapentaenoic/docosahexae-
noic, an n-3 fatty acid. The eicosanoids are considered
as local hormones that includep r o s t a n o i d s( i . e .P G s ,
prostacyclins and thromboxanes), LTs, lipoxins, hepoxi-
lins and hydroxyeicosatetraenoic (HETE) acid. They are
important homeostatic or proinflammatory lipid media-
tors that exert autocrine and paracrine activities in
diverse physiologic responses (e.g. vasomodulation, pla-
telet aggregation and bronchodilatation). Of more rele-
vance here, PGs and LTs strongly regulate our innate
and humoral immunity responses. Production of several
eicosanoids is considerably increased during inflamma-
tion, and they are involved in the pathogenesis of var-
ious diseases.
Biosynthesis pathway from AA
Once cells are exposed to different physiological or
pathological stimuli such as cytokines, growth factors or
physical trauma, AA is cleaved from membrane phos-
pholipids by the action of the enzyme phospholipase A2
(PLA2) (Figure 1). From then on, the free fatty acid may
undergo transformation either through the cyclooxygen-
ase (COX) pathway, giving rise to PGs, or through the
lipoxygenase pathway, notably producing LTs. In the lat-
ter case, AA is transferred by the five-lipoxygenase acti-
vating protein (FLAP) to 5-lipoxygenase (5-LO), an
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Page 3 of 14Figure 1 Metabolic pathway of AA transformation into eicosanoid products. Once a cell is activated by a proinflammatory stimulus that
engages a Gaq-coupled seven-transmembrane receptor, AA can be cleaved by cytosolic PLA2 from phospholipids that compose cellular
membranes (mostly nuclear, endoplasmic reticulum or Golgi membranes)[173]. Free AA can subsequently be converted into different eicosanoid
products by different enzymes (represented in blue), notably the COX and LO pathways. This review will mainly focus on the prostanoids - PGE2,
and 15d-PGJ2 prostaglandins - and on 5-LO products, namely LTs. Only eicosanoids and pathways of interest in this paper are depicted.
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Thereafter, 5-LO converts AA into LTA4 [63]. This
unstable intermediate can then be metabolized into
LTB4 by LTA4 hydrolase or into LTC4 by LTC4
synthase [64]. On the other hand, PGs are produced by
most nucleated cells in our body, and formed by the
rate-limiting COXs. COX-1 is generally thought to be a
constitutively expressed enzyme, while COX-2 is highly
inducible under inflammatory conditions through the
control of the ubiquitous mammalian transcription fac-
tor NF-kB [65,66]. COX-2 is especially important in
cells that are involved in inflammation, such as macro-
phages and monocytes, and is responsible for the synth-
esis of those prostanoids involved in severe
inflammatory states. It is noteworthy that, in the brain,
an alternatively spliced COX-1 isoform, termed COX-3,
might also be in play [67,68]. COX enzymes produce
PGH2, which is then converted into several isomers via
various cell-specific synthases, as reviewed by [69].
Biological functions
It has been well documented that PGs are important
homeostatic or proinflammatory lipid mediators which
act in an autocrine and paracrine manner. They are
implicated in a wide array of biological functions such as
vasoconstriction, vasodilatation, aggregation, chemotaxis,
fever, pain response and asthma [70]. This family of
potent hormone-like substances include PGE2,P G D 2,
and PGF2a.A sf o rP G D 2, it can subsequently be con-
verted into the J class of PGs, which include the cyclo-
pentenone 15d-PGJ2 [71-73]. PGE2 is a well-known
inflammatory modulator implicated in diverse physiologi-
cal conditions such as vasodilatation, pain, fever, relaxing
of smooth muscles, neuronal function and inhibition of
noradrenalin release from sympathetic nerve terminals.
As for 15d-PGJ2, this PG is produced in mast cells, plate-
lets and alveolar macrophages. It has been documented
as a potent inflammatory regulator, given its capacity to
inhibit cytokine secretion and functions of both antigen-
presenting cells and T lymphocytes [74,75].
LTs are potent proinflammatory mediators, which are
involved in many innate immunological processes such
as leukocyte adhesion, chemotaxis and activation
[70,76]. They regulate the immune response to different
stimuli, and are known to play an important role in
asthma, vascular disease, cancer and other pathological
conditions [77]. Produced in leukocytes, LTs include
LTB4 and several cysteinyl leukotrienes (cysLTs) (e.g.
LTC4, LTD4 and LTE4) (Figure 1). LTB4 is known as a
potent chemoattractant, also capable of inducing the
formation of reactive oxygen species and the release of
lysosome enzymes by most leukocytes. Known as the
slow-reacting substances of anaphylaxis, cysLTs induce
inflammation, and may also, when in excess, induce
anaphylactic shock. Macrophages produce both LTB4
and CysLTs. As part of the innate immune response,
antimicrobial effector functions modulated by LTs
include direct effects, such as promotion of leukocyte
accumulation and enhancement of macrophages and
neutrophils microbe phagocytosis and killing capacity, as
well as indirect effects, via the production of other
inflammatory molecules [78].
The recently-discovered eoxins are closely related to
cysLTs, and are also proinflammatory, but are produced
via the 12/15-LO pathways. For instance, 15-HETE is
produced from AA in most immune cells which carry
15-LO, such as neutrophils [79], endothelial cells [80],
and macrophages [81]. This lipid mediator is mainly
produced during inflammatory and immunological con-
ditions, and is known to modulate inflammatory diseases
by influencing different biological responses such as
chemotaxis, hormone secretion, ion transport and var-
ious enzymatic pathways in a receptor-specific manner.
Although its extracellular receptor remains to be identi-
fied, 15-HETE is known to serve as an endogenous
ligand for the peroxisome proliferators activated recep-
tors [82,83].
LT and PG receptors
Eicosanoids mostly exert their effects by binding to
seven transmembrane-spanning receptors, more specifi-
cally Gq- and Gi-protein coupled receptors (GPCR),
found on most leukocytes. Engagement of an LT recep-
tor is generally associated with a decrease of cyclic ade-
nosine monophosphate (cAMP) and an increase in
intracellular calcium followed by an activation of phos-
phatidyl inositol 3-kinase, protein kinase C, MAP kinase,
Rac and NF-kB [84-87]. The receptors for LTB4 are
known as LTB4 receptor 1 (LTB4 receptor, or BLT1) - a
high affinity receptor, and BLT2 - a low affinity recep-
tor. BLT1 is preferentially expressed on leukocytes,
while BLT2 is ubiquitously expressed. CysLTs engage
cysLT1, cysLT2 or GPR17 receptors [77,88,89], although
the latter may regulate the signalling from cysLT1 in
response to cysLTs [90].
Regarding PGs, they act on a broader range of recep-
tors. PGE2, for example, will engage E-prostanoid recep-
tors EP1, EP2, EP3 or EP4, which each has distinct
biochemical properties and tissue and cellular localiza-
tion, which explains the very disparate effects of this
PG, depending on the cell type [91]. As for 15d-PGJ2,
no specific receptor has been identified to date. Instead,
it has been shown to act via PGD2 receptors (DP1 and
DP2) and through interaction with intracellular targets,
including nuclear receptors and non-receptor proteins
[92]. In particular, 15d-PGJ2 is recognized as the endo-
genous ligand for the intranuclear receptor peroxisome
proliferator-activated receptor-g (PPAR-g) [74].
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HIV, outside the CNS
PGs and HIV
The anti-HIV properties of PGs are well documented
[93-96]. However, only a handful of studies have
attempted to elucidate the mechanisms involved. For
example, it has been clearly shown that PGE2 induces
resistance of monocyte-derived macrophages (MDMs)
to HIV infection by negatively modulating the surface
expression of CCR5 - the main coreceptor used by R5-
tropic strains to enter host cells in a pH-independent
manner. It does so through augmentation of cAMP cel-
lular concentration [97] which, in turn, activates a pro-
tein kinase A (PKA)-dependent mechanism [98]. One
may speculate that activation of PKA through a cAMP
increase may regulate CCR5 levels by heterologous
desensitization (whereby the activation of a GPCR by its
agonist causes downregulation of another GPCR on the
same cell). In correlation to these findings, a recent
study has shown that over-expression of PG synthase-2
greatly reduces the levels of HIV replication in primary
human monocuclear cells [99]. These observations are,
however, in contrast to a study by Dumais and collea-
gues showing that PGE2 can facilitate HIV production
in a T cell line by inducing transcriptional activation of
the virus regulatory elements (i.e. long terminal repeat/
LTR) [100]. This discrepancy could be explained by the
different cell types used in the two studies and the nat-
ure of the PGs involved, which do not act via the same
signalling pathways. Indeed, PTGS2 is known to down-
regulate NF-B-mediated transcription, whereas PGE2
activates this same transcription factor.
Another potent PG exerting antiviral activities, 15d-
PGJ2, inhibits transcriptional activation of HIV LTR by
antagonizing NF-B in colonic epithelial cells through a
PPAR-g-independent mechanism [101]. It has been
recently observed in human macrophages that 15d-PGJ2
can also modify free thiols in the viral transactivating
Tat protein, thus suppressing its transactivation function
[102]. Altogether, certain PGs can now be considered as
anti-HIV eicosanoids and may very well contribute to
the limitation of the systemic viral load in HIV-infected
individuals.
LTs and HIV
Several studies have already shown how endogenous
LTs play a critical role in the innate immune defence
against bacterial and viral infections [103-107]. Regard-
ing the response to HIV, most of our knowledge con-
cerns LTB4. As early as 1989, Thorsen and colleagues
noticed that neutrophils isolated from patients infected
with HIV display a reduced capacity of producing LTB4
[108]. Another group later demonstrated that, in HIV-
infected subjects, a defect could be observed in the 5-
LO metabolic capacity of lung alveolar macrophages,
which are resident cells primarily responsible for main-
taining the sterility in the lungs. This diminished 5-LO
efficiency was associated with a decreased expression of
both 5-LO and FLAP in HIV-infected patients display-
ing low CD4 T-cell counts (< 200/mm
3) [109]. The
same tendencies were observed in polymorphonuclear
c e l l s( P M N s )f r o ms u b j e c t sw i t hl o wC D 4T - c e l lc o u n t s
[110]. This decrease of LT synthesis capacity in alveolar
macrophages and PMNs may negatively modulate the
innate immune response to challenges by pathogens and
opportunistic infections in the lungs during the late
phase of HIV infection. For example, 5-LO knockout
(KO) mice have a reduced survival rate after being
inoculated intratracheally with K. pneumoniae,a sc o m -
pared to wild-type mice [111].
Recently, the existence of several 5-LO isoforms has
been discovered in different human cell types (i.e.
monocytes, B cells and PMNs). All cells examined
express the full-length mRNA. On the other hand, the
alternative forms of 5-LO appear to be expressed in a
cell-type or cell-line specific manner. By themselves,
these alternative isoforms are enzymatically inactive.
Interestingly, the coexpression of these isoforms with
the full-length 5-LO affects the capacity of cells to
synthesize LTs [112]. How HIV infection can negatively
modulate the LT production capacity of cells (i.e. alveo-
lar macrophages and PMNs) remains to be explained.
One may speculate that the 5-LO inefficacy brought
about by HIV infection might be due to the upregula-
tion of inactive 5-LO isoforms in cells, resulting in a
downmodulation of their LT synthesis capacity. Addi-
tional studies are warranted to validate this hypothesis.
In general, LTs are considered to be mediators of anti-
microbial host defence. In humans, administration of
LTB4 to healthy individuals induces a plasmatic increase
of a-defensins and MIP-1b, both well-known antiviral
proteins. Interestingly, PMNs isolated from HIV-infected
and non-infected subjects secrete similar amounts of a-
defensins in response to LTB4 activation [113], meaning
that this LT can induce an antiviral response whether or
not PMNs are exposed to HIV. Moreover, the secretome
of PMNs obtained from healthy individuals treated with
LTB4 contains several antimicrobial proteins including
a-defensins, cathepsin G, elastase, lysozyme C, and LL-
37, which significantly attenuates infectivity of both X4-
and R5-tropic HIV variants [114].
Non-steroidal anti-inflammatory drugs and HIV
As they constitute COX inhibitors, it is relevant to dis-
cuss here the anti-HIV potential of non-steroidal anti-
inflammatory drugs (NSAIDs). In the HAART era, rheu-
matic manifestations have been reported to affect 9% of
HIV-infected patients [115], and up to 60% of untreated
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the first line of medication prescribed. Indeed, many
anti-inflammatory compounds (such as platelet-activat-
ing factor (PAF) receptor antagonist, aspirin and indo-
methacin) have demonstrated a certain anti-HIV
potential. Interestingly, o-(acetoxyphenyl)hept-2-ynyl
sulfide (APHS), an aspirin-derived molecule, has proven
to be a compound with important anti-HIV properties.
More precisely, APHS can act as a potent HIV inhibitor
by negatively modulating Gag DNA synthesis during the
reverse transcription (RT) process [119]. In addition,
APHS can also act synergically with clinically available
reverse transcriptase and protease inhibitors to inhibit
several strains of HIV under in vitro conditions [120].
However, not all NSAIDs show anti-HIV properties. For
instance, we have evaluated whether NS-398, another
potent COX inhibitor [121], albeit specific for COX-2,
could affect HIV replication in both MDMs and MDMi.
We found that NS-398 does not significantly modulate
HIV infection in these two distinct cellular models
(unpublished data). This indicates that some mechanism
other than the anti-COX-2 activities of APHS must be
responsible for its anti-HIV potential. Interestingly, a
recent clinical study has shown that celecoxib, another
widely used COX-2 inhibitor, when administered to
HIV-infected patients without antiretroviral treatment,
downmodulates the immune activation related to clini-
cal progression of chronic HIV infection and improves
T cell-dependent functions in vivo. Indeed, a reduction
in surface expression of CD38 and programmed death-1
is observed in cytotoxic T cells. Furthermore, the cele-
coxib treatment enhances the number of regulatory T
cells and improves the humoral memory recall
responses to a T cell-dependent vaccine [122]. Given
the obvious beneficial potential of NSAIDs ability to
modulate, either directly or indirectly, the replication
cycle of HIV and the progressive immune dysfunctions
occurring throughout the course of the disease, a better
characterization of the mechanisms of action of these
drugs is warranted.
5. Eicosanoids present in the CNS
Eicosanoids produced in the CNS play an important role
in neuropathogenesis. Several different studies, mainly
based on murine models, have shown that microglial
cells produce many COX and 5-LO products, namely
PGE2,P G D 2,L T B 4,L T C 4, 5-HETE, 11-HETE and 15-
HETE [123-128]. Brain eicosanoids may also be secreted
by cell types other than microglia, such as astrocytes,
oligodendrocytes, neurons and endothelial cells, which
play an important role in the propagation and mainte-
nance of neuroinflammation [129,130].
Not surprisingly, eicosanoid-producing enzymes COXs
and lipoxygenases have also been detected in the CNS,
either at the mRNA or protein level (Table 1). These
enzymes are known to be stimulated during neuroin-
flammation [131]. For example, 5-LO is expressed in the
CNS and has been known to be present in neurons,
microglia and astrocyte cells [126,132-136]. As for
COX-2, it is induced in most cells of the CNS, including
neurons, microglia, astrocytes and oligodendrocytes
[128,137-139]. Furthermore, microarray analysis has
revealed that activation of mixed glial cells (predomi-
nately microglia) leads to striking increases in the
expression of FLAP, 5-LO, 15-LO, COX-2, and PLA2,
which are all HAD-associated gene products involved in
LT or PG synthesis [27]. Moreover, a COX-1 splice var-
iant, termed COX-3 or COX-1b, has also been detected
at both the mRNA and protein levels in human brain
tissues [140]. It has been shown to catalyze the synthesis
of PGF2□, although less efficiently than COX-1.
Different prostanoid receptors, such as EP1-4 (recep-
tor for PGE2), DP1-2 (receptor for PGD2), FP (receptor
for PGF2a), and IP (receptor for PGI2), are found in the
CNS, and their level of expression is often linked to the
severity of cognitive impairment [128,141,142] (Table 1).
Meanwhile, the main LT receptors expressed in the
human and murine CNS, more specifically by neurons,
Table 1 Summary table of the different receptors and
eicosanoid-producing enzymes known to be found in the
CNS and discussed in this review.
Cells Receptors Enzymes
Microglia cysLT1
131 COX-2
123, 127, 135, 138
cysLT2
124 5-LO
124, 125, 132
EP4
141 FLAP
132
EP2
141 COX-1
128, 135, 137
PLA2
27
Astrocytes EP2
141 5-LO
133
COX-2
138
PLA2
129
12-LO
130
Oligodendrocytes GPR17
145 COX-2
138
12-LO
130
Neurons BLT1
131 5-LO
133, 135
GPR17
89, 145 COX-2
128, 134
cysLT2
144 12-LO
130
EP2
141
EP1
141
EP3
141
EP4
141
Endothelial cells cysLT2
147
EP4
141
Unspecified DP1-2
128
CNS cell types FP
128
IP
128
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cysLT2 and GPR17 [89,143-148].
The eicosanoids present in the CNS, whether or not
they are produced by microglia, contribute greatly to
neuroinflammation and HAD, as proinflammatory lipid
mediators. In fact, the expression profile of 5-LO and
COX products and of their receptors might serve as bio-
markers for detecting CNS pathologies and their degree
of severity.
6. Interactions between HIV and eicosanoids in
the CNS
It is well known that elevated amounts of eicosanoids
can be found in the brain and CSF of HIV-infected indi-
viduals [142,149]. Likewise, an upregulation of COX-2
expression is observed in in vitro cocultures of HIV-
infected macrophages and brain endothelial cells, as well
as in brain-derived cell lines exposed to soluble viral
proteins [150-152]. We are, however, only starting to
understand how eicosanoids interact with HIV. This
section will focus on the complex direct or indirect
interactions between HIV and COX-2, 5-LO and their
products in the CNS, and on how this interplay might
influence the progression of HIV-associated neurological
impairments (Table 2).
Relationship between HIV and COX-2 and its products
Although it is widely accepted that neurons do not sup-
port productive infection with HIV, there is clear evi-
dence of neuronal loss in brains of HIV-infected
individuals [44,153,154]. The viral surface glycoprotein
gp120 is known to be greatly responsible for inducing
neuroinflammation and neurodegeneration [155-158].
Interestingly, in vitro and in vivo studies have shown
that enhanced COX-2 expression and PGE2 synthesis
are involved in apoptosis observed in the CNS of rats
following intracerebroventricular injection of gp120
[159-161]. Moreover, the varying degree of severity of
neuroinflammation brought about by gp120 from differ-
ent HIV clades is notably linked to the level of synthesis
of certain COX products. Indeed, a recent study has
indicated that human primary astrocytes exposed to
purified gp120 from HIV clade B produce higher levels
of COX-2 than astrocytes exposed to gp120 from clade
C [162]. However, the mechanisms through which
gp120 induces COX-2 expression in the brain are still
not fully understood. In vitro and in vivo data have
r e v e a l e dar o l ef o rI L - 1 b in mediating neurotoxicity
induced by gp120 [163,164]. It has been shown that
HIV gp120 can induce COX-2 expression not only in
neuroblastoma cells, but also in astrocytoma cells
through an NF-B-mediated signal transduction path-
way [151,152]. Furthermore, a recent study shows that
the capacity of gp120 to induce COX-2 and its products
in microglial cells greatly depends on the presence of
IFNg [7]. These data suggest that the IL-1b and IFNg-
mediated COX-2 expression and PGE2 synthesis trig-
gered by HIV gp120 in the CNS may account for the
observed neuronal dysfunction. Thus, gp120 may be
considered as a viral factor that potently induces neu-
roinflammation via COX-2 by interacting directly with
cells of the CNS.
Another viral protein known to be released in the sur-
rounding environment following HIV infection is Tat. It
has been shown that both Tat and COX-2 are involved
in the neuropathogenesis associated with HIV infection.
For example, the upregulated expression of COX-2 in
the BBB endothelial cells and macrophages brought on
by HIV infection has been attributed, at least partly, to
Tat-induced alterations of occludin expression, leading
to the loss of tight junction integrity and the BBB break-
down [150,165]. Furthermore, an increase in COX-2
expression and PGE2 production is observed in astrocy-
toma cell lines and primary human astrocytes treated
with Tat [166]. The intrahippocampal injection of Tat in
mice induces a COX-2 expression not only in astrocytes,
but also in microglial cells. Moreover, the proinflamma-
tory effect of Tat is significantly attenuated upon treat-
ment with the COX-2 inhibitor NS-398, which
demonstrates the involvement of COX-2 in the Tat-
Table 2 Summary table of the known relationships between eicosanoids and HIV in the CNS.
Exposure to Type of cells or mode of exposure Species Product Effect Mediated by Citation
gp120 intracerebral injection rat PGE2 neuronal apoptosis IL-1b 159, 160
gp120 intracerebral injection rat PGE2 neuronal apoptosis N/A 161
gp120 astrocytes human PGE2 neurotoxicity N/A 162
gp120 neurons human N/A neurotoxicity 5-LO/PGHS 172
Tat intracerebral injection mouse COX-2 Neuroinflammation NFKb 166
Tat tail vein injection mouse COX-2 BBB disruption N/A 165
LTs microglia human N/A HIV inhibition PKC unpublished
HIV-1 endothelial cells/macrophages human COX-2 Neuroinflammation IL-1b 150
N/A: Non available data
PGHS: prostaglandin H synthase
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Page 8 of 14induced neuropathogenesis [167]. Hence, exposure of
astrocytes and microglia to either fully competent HIV
particles or viral proteins promotes secretion of several
proinflammatory molecules, including eicosanoid pro-
ducts, which greatly influences neuroinflammation and
contributes to the severity of HIV-associated neurocog-
nitive complications. This may be further explained by
recent findings indicating that coculture with HIV-
infected astrocytes is sufficient to increase the produc-
tion of neurotoxic molecules released by virus-infected
microglia such as PPP4R2, HSPA9 and NAP1L1 (pro-
teins that regulate neuronal apoptosis) [61]. Although
the role of COX-2 in brain inflammation is still not
fully recognized, one may speculate that neurological
complications that occur throughout the course of HIV
infection may be in part mediated by COX-2 and its
products. Another point to consider concerning HIV-
infected patients is the potential effect of antiretrovirals
on eicosanoids. For instance, maraviroc, a widely used
CCR5 antagonist, is known to induce PG synthesis in
microglia, thus strengtheningt h e i rp r o i n f l a m m a t o r y
activation, which is likely to exacerbate neurological
complications [7].
Relationship between HIV and LTs
Although previous studies have produced evidence of
the anti-microbial properties of LTs, only recently have
we established the relationship between LTs and viral
infections in the CNS. For example, Chen and collea-
gues have shown that, during early infection with vesi-
cular stomatitis virus, mice treated with the 5-LO
antagonist Zileuton and 5-LO knock-out mice both pre-
sented an impaired infiltration process of neutrophils
into the CNS, as well as fewer neurons expressing nitric
oxide synthase-1, higher viral titres and increased dis-
ruption of the BBB [104]. These data clearly showed the
protective role of LTs during viral infections in the CNS.
We now know that LTs are present in the CNS of
HIV-infected individuals, where they can be produced
by different cell types, including monocytes and micro-
glia [125,126,149,168]. Moreover, recent studies have
shown that high concentrations of eicosanoids, including
LTB4, and several other AA cascade markers are found
in the brain of HIV-transgenic rats [169,170]. In fact,
cocultures of astroglial cell sa n dH I V - i n f e c t e dm o n o -
cytes release high levels of AA-derived metabolites, such
as LTB4 and LTD4 [171], which can lead to neuroin-
flammation and neurotoxicity. Furthermore, gp120
induces necrotic death of human neuroblastoma cells by
activating 5-LO [172]. This issue is, however, not with-
out controversy since it has been shown that expression
and activity of 5-LO can actually decrease in the rat
neocortex upon the intracerebroventricular injection of
gp120 [161]. The vast differences between the
microenvironment of neuronal cells found in the rat
brain neocortex upon gp120 intrathecal injection and
the one studied in an in vitro experimental setup con-
sisting of a single human cell type may account for the
observed opposite effects of gp120 on 5-LO regulation.
Interestingly, our laboratory has shown that LTB4 and
LTC4 negatively modulate HIV infection in MDMi’si na
protein kinase C-dependent manner (unpublished obser-
vations). This phenomenon may be explained in part by
the fact that LTs inhibit the pH-independent fusion step
of the infection by decreasing the levels of CCR5 on the
cell surface. Moreover, decreased amounts of proviral
DNA are found in LT-treated MDMi’s, while RT pro-
ducts remain unaffected by LTs, indicating a blockage
between the RT and integration steps of the infection.
Although LTs present in the CNS may exert an anti-
HIV effect, it is possible that HIV can counteract this
phenomenon by inhibiting their production. On the
other hand, a neurotoxic response induced by HIV
infection in the CNS can also be mediated through 5-
LO products. The balance between the anti-HIV effect
of LTs and their neuroinflammatory/neurotoxic effect
might be pivotal in the development of neuroAIDS.
Further research will be needed to better define the role
played by LTs in the neuropathogenesis associated with
HIV infection.
7. Conclusion
In summary, HIV-associated neurological impairments
continue to be an important issue in the HAART era.
We have learned that HIV-induced inflammation in the
CNS, caused primarily by microglia and astrocytes, is
greatly responsible for the neurological symptoms
observed in virus-infected individuals. Importantly, mul-
tiple markers of brain AA metabolism are upregulated
in the HIV-infected CNS, which may be correlated with
dementia severity and behavioural deficits. The direct
role of these potent inflammatory lipid mediators in the
development and progression of the disease is still
unfortunately poorly understood. Recent advances in the
field have shown that COX and 5-LO products can
negatively modulate HIV infection in different host cells.
Therefore, PGs and LTs produced by innate immune
cells may have an important role in controlling HIV
replication, maybe more specifically in the CNS. This
may explain, at least partially, how the viral load is often
maintained at lower titres in this compartment than in
the peripheral blood; the degree of penetration of antire-
troviral agents in the CNS and their efficacy in the brain
tissue also remain, of course, to be fully investigated.
We should examine more closely eicosanoid products
in the CNS of infected individuals in the perspective of
their ability to control the viral burden in this compart-
ment, even though they are often associated with
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Page 9 of 14neuroinflammatory complications. In other regards, it
would be worth evaluating the usefulness of eicosanoids
as biomarkers to assess the severity of HIV-induced
neurological impairments.
Author details
1Centre de Recherche en Infectiologie, Centre Hospitalier Universitaire de
Québec - CHUL, 2705 boul. Laurier, Québec (QC), Canada, G1V 4G2.
2Département de Microbiologie-Infectiologie et Immunologie, Faculté de
médecine, Université Laval, Québec, Canada.
Authors’ contributions
JB carried out most of the literature research and the first draft. SM
participated in the drafting and research of the literature. CB and MJT
carefully reviewed the manuscript. All authors read and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 26 October 2011 Accepted: 11 January 2012
Published: 11 January 2012
References
1. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL, Merlin TL, Young SA,
Mills RG, Wachsman W, Wiley CA: Early viral brain invasion in iatrogenic
human immunodeficiency virus infection. Neurology 1992, 42:1736-1739.
2. Kraft-Terry SD, Stothert AR, Buch S, Gendelman HE: HIV-1 neuroimmunity
in the era of antiretroviral therapy. Neurobiol Dis 2010, 37:542-548.
3. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB,
Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J,
Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L,
Robertson KR, Sacktor N, Valcour V, Wojna VE: Updated research nosology
for HIV-associated neurocognitive disorders. Neurology 2007,
69:1789-1799.
4. Evers S, Rahmann A, Schwaag S, Frese A, Reichelt D, Husstedt IW:
Prevention of AIDS dementia by HAART does not depend on
cerebrospinal fluid drug penetrance. AIDS Res Hum Retroviruses 2004,
20:483-491.
5. Wright E: Neurocognitive impairment and neuroCART. Curr Opin HIV AIDS
2011, 6:303-308.
6. Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E,
Bracciale L, Tamburrini E, Cauda R, De Luca A, Silveri MC: Efavirenz
associated with cognitive disorders in otherwise asymptomatic HIV-
infected patients. Neurology 2011, 76:1403-1409.
7. Lisi L, Tramutola A, De Luca A, Navarra P, Dello Russo C: Modulatory
effects of the CCR5 antagonist maraviroc on microglial pro-inflammatory
activation elicited by gp120. J Neurochem 2011, 120:106-114.
8. Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG,
Peytavin G, Tubiana R, Pialoux G, Katlama C: Discordance between
cerebral spinal fluid and plasma HIV replication in patients with
neurological symptoms who are receiving suppressive antiretroviral
therapy. Clin Infect Dis 2010, 50:773-778.
9. Christo PP, Greco DB, Aleixo AW, Livramento JA: HIV-1 RNA levels in
cerebrospinal fluid and plasma and their correlation with opportunistic
neurological diseases in a Brazilian AIDS reference hospital. Arq
Neuropsiquiatr 2005, 63:907-913.
10. De Luca A, Ciancio BC, Larussa D, Murri R, Cingolani A, Rizzo MG,
Giancola ML, Ammassari A, Ortona L: Correlates of independent HIV-1
replication in the CNS and of its control by antiretrovirals. Neurology
2002, 59:342-347.
11. Price RW, Spudich S: Antiretroviral therapy and central nervous system
HIV type 1 infection. J Infect Dis 2008, 197(Suppl 3):S294-306.
12. Gisslen M, Fuchs D, Svennerholm B, Hagberg L: Cerebrospinal fluid viral
load, intrathecal immunoactivation, and cerebrospinal fluid monocytic
cell count in HIV-1 infection. J Acquir Immune Defic Syndr 1999, 21:271-276.
13. Gisslen M, Svennerholm B, Norkrans G, Franzen C, Sall C, Svensson R,
Oberg S, Hagberg L: Cerebrospinal fluid and plasma viral load in HIV-1-
infected patients with various anti-retroviral treatment regimens. Scand J
Infect Dis 2000, 32:365-369.
14. Schnell G, Spudich S, Harrington P, Price RW, Swanstrom R:
Compartmentalized human immunodeficiency virus type 1 originates
from long-lived cells in some subjects with HIV-1-associated dementia.
PLoS Pathog 2009, 5:e1000395.
15. Witwer KW, Gama L, Li M, Bartizal CM, Queen SE, Varrone JJ, Brice AK,
Graham DR, Tarwater PM, Mankowski JL, Zink MC, Clements JE:
Coordinated regulation of SIV replication and immune responses in the
CNS. PLoS One 2009, 4:e8129.
16. Barber SA, Herbst DS, Bullock BT, Gama L, Clements JE: Innate immune
responses and control of acute simian immunodeficiency virus
replication in the central nervous system. J Neurovirol 2004, 10(Suppl
1):15-20.
17. Hult B, Chana G, Masliah E, Everall I: Neurobiology of HIV. Int Rev Psychiatry
2008, 20:3-13.
18. Ivey NS, MacLean AG, Lackner AA: Acquired immunodeficiency syndrome
and the blood-brain barrier. J Neurovirol 2009, 15:111-122.
19. Yadav A, Collman RG: CNS inflammation and macrophage/microglial
biology associated with HIV-1 infection. J Neuroimmune Pharmacol 2009,
4:430-447.
20. Gonzalez-Scarano F, Martin-Garcia J: The neuropathogenesis of AIDS. Nat
Rev Immunol 2005, 5:69-81.
21. Wu DT, Woodman SE, Weiss JM, McManus CM, D’Aversa TG, Hesselgesser J,
Major EO, Nath A, Berman JW: Mechanisms of leukocyte trafficking into
the CNS. J Neurovirol 2000, 6(Suppl 1):S82-85.
22. Dohgu S, Banks WA: Lipopolysaccharide-enhanced transcellular transport
of HIV-1 across the blood-brain barrier is mediated by the p38 mitogen-
activated protein kinase pathway. Exp Neurol 2008, 210:740-749.
23. Wang H, Sun J, Goldstein H: Human immunodeficiency virus type 1
infection increases the in vivo capacity of peripheral monocytes to cross
the blood-brain barrier into the brain and the in vivo sensitivity of the
blood-brain barrier to disruption by lipopolysaccharide. J Virol 2008,
82:7591-7600.
24. Ancuta P, Kamat A, Kunstman KJ, Kim EY, Autissier P, Wurcel A, Zaman T,
Stone D, Mefford M, Morgello S, Singer EJ, Wolinsky SM, Gabuzda D:
Microbial translocation is associated with increased monocyte activation
and dementia in AIDS patients. PLoS One 2008, 3:e2516.
25. Strazza M, Pirrone V, Wigdahl B, Nonnemacher MR: Breaking down the
barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res 2011,
1399:96-115.
26. Alexaki A, Liu Y, Wigdahl B: Cellular reservoirs of HIV-1 and their role in
viral persistence. Curr HIV Res 2008, 6:388-400.
27. Albright AV, Gonzalez-Scarano F: Microarray analysis of activated mixed
glial (microglia) and monocyte-derived macrophage gene expression. J
Neuroimmunol 2004, 157:27-38.
28. Coisne C, Engelhardt B: Tight junctions in brain barriers during central
nervous system inflammation. Antioxid Redox Signal 2011, 15:1285-1303.
29. Chan WY, Kohsaka S, Rezaie P: The origin and cell lineage of microglia:
new concepts. Brain Res Rev 2007, 53:344-354.
30. Kaur C, Hao AJ, Wu CH, Ling EA: Origin of microglia. Microsc Res Tech 2001,
54:2-9.
31. Monier A, Adle-Biassette H, Delezoide AL, Evrard P, Gressens P, Verney C:
Entry and distribution of microglial cells in human embryonic and fetal
cerebral cortex. J Neuropathol Exp Neurol 2007, 66:372-382.
32. Cuadros MA, Navascues J: The origin and differentiation of microglial
cells during development. Prog Neurobiol 1998, 56:173-189.
33. Davoust N, Vuaillat C, Androdias G, Nataf S: From bone marrow to
microglia: barriers and avenues. Trends Immunol 2008, 29:227-234.
34. Buckner CM, Calderon TM, Willams DW, Belbin TJ, Berman JW:
Characterization of monocyte maturation/differentiation that facilitates
their transmigration across the blood-brain barrier and infection by HIV:
implications for NeuroAIDS. Cell Immunol 2011, 267:109-123.
35. McManus CM, Brosnan CF, Berman JW: Cytokine induction of MIP-1 alpha
and MIP-1 beta in human fetal microglia. J Immunol 1998, 160:1449-1455.
36. Matsumoto Y, Ohmori K, Fujiwara M: Microglial and astroglial reactions to
inflammatory lesions of experimental autoimmune encephalomyelitis in
the rat central nervous system. J Neuroimmunol 1992, 37:23-33.
37. Matsumoto Y, Ohmori K, Fujiwara M: Immune regulation by brain cells in
the central nervous system: microglia but not astrocytes present myelin
Bertin et al. Retrovirology 2012, 9:4
http://www.retrovirology.com/content/9/1/4
Page 10 of 14basic protein to encephalitogenic T cells under in vivo-mimicking
conditions. Immunology 1992, 76:209-216.
38. Bauer J, Sminia T, Wouterlood FG, Dijkstra CD: Phagocytic activity of
macrophages and microglial cells during the course of acute and
chronic relapsing experimental autoimmune encephalomyelitis. J
Neurosci Res 1994, 38:365-375.
39. Lee SC, Liu W, Dickson DW, Brosnan CF, Berman JW: Cytokine production
by human fetal microglia and astrocytes. Differential induction by
lipopolysaccharide and IL-1 beta. J Immunol 1993, 150:2659-2667.
40. Gorry PR, Bristol G, Zack JA, Ritola K, Swanstrom R, Birch CJ, Bell JE,
Bannert N, Crawford K, Wang H, Schols D, De Clercq E, Kunstman K,
Wolinsky SM, Gabuzda D: Macrophage tropism of human
immunodeficiency virus type 1 isolates from brain and lymphoid tissues
predicts neurotropism independent of coreceptor specificity. J Virol 2001,
75:10073-10089.
41. Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O’Connor MJ, Doms RW,
Gonzalez-Scarano F: Microglia express CCR5, CXCR4, and CCR3, but of
these, CCR5 is the principal coreceptor for human immunodeficiency
virus type 1 dementia isolates. J Virol 1999, 73:205-213.
42. Agrawal L, Maxwell CR, Peters PJ, Clapham PR, Liu SM, Mackay CR,
Strayer DS: Complexity in human immunodeficiency virus type 1 (HIV-1)
co-receptor usage: roles of CCR3 and CCR5 in HIV-1 infection of
monocyte-derived macrophages and brain microglia. J Gen Virol 2009,
90:710-722.
43. Aasa-Chapman MM, Aubin K, Williams I, McKnight A: Primary CCR5 only
using HIV-1 isolates does not accurately represent the in vivo replicating
quasi-species. Virology 2006, 351:489-496.
44. Adle-Biassette H, Chretien F, Wingertsmann L, Hery C, Ereau T, Scaravilli F,
Tardieu M, Gray F: Neuronal apoptosis does not correlate with dementia
in HIV infection but is related to microglial activation and axonal
damage. Neuropathol Appl Neurobiol 1999, 25:123-133.
45. Jones MV, Bell JE, Nath A: Immunolocalization of HIV envelope gp120 in
HIV encephalitis with dementia. Aids 2000, 14:2709-2713.
46. Viviani B, Corsini E, Binaglia M, Galli CL, Marinovich M: Reactive oxygen
species generated by glia are responsible for neuron death induced by
human immunodeficiency virus-glycoprotein 120 in vitro. Neuroscience
2001, 107:51-58.
47. Corasaniti MT, Bagetta G, Rotiroti D, Nistico G: The HIV envelope protein
gp120 in the nervous system: interactions with nitric oxide, interleukin-
1beta and nerve growth factor signalling, with pathological implications
in vivo and in vitro. Biochem Pharmacol 1998, 56:153-156.
48. Hudson L, Liu J, Nath A, Jones M, Raghavan R, Narayan O, Male D, Everall I:
Detection of the human immunodeficiency virus regulatory protein tat
in CNS tissues. J Neurovirol 2000, 6:145-155.
49. Leone C, Le Pavec G, Meme W, Porcheray F, Samah B, Dormont D, Gras G:
Characterization of human monocyte-derived microglia-like cells. Glia
2006, 54:183-192.
50. Cherrier T, Suzanne S, Redel L, Calao M, Marban C, Samah B, Mukerjee R,
Schwartz C, Gras G, Sawaya BE, Zeichner SL, Aunis D, Van Lint C, Rohr O:
p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and
SUV39H1. Oncogene 2009, 28:3380-3389.
51. Williams R, Bokhari S, Silverstein P, Pinson D, Kumar A, Buch S: Nonhuman
primate models of NeuroAIDS. J Neurovirol 2008, 14:292-300.
52. Gorry PR, Ong C, Thorpe J, Bannwarth S, Thompson KA, Gatignol A,
Vesselingh SL, Purcell DF: Astrocyte infection by HIV-1: mechanisms of
restricted virus replication, and role in the pathogenesis of HIV-1-
associated dementia. Curr HIV Res 2003, 1:463-473.
53. Vijaykumar TS, Nath A, Chauhan A: Chloroquine mediated molecular
tuning of astrocytes for enhanced permissiveness to HIV infection.
Virology 2008, 381:1-5.
54. Canki M, Thai JN, Chao W, Ghorpade A, Potash MJ, Volsky DJ: Highly
productive infection with pseudotyped human immunodeficiency virus
type 1 (HIV-1) indicates no intracellular restrictions to HIV-1 replication
in primary human astrocytes. J Virol 2001, 75:7925-7933.
55. Thompson KA, Cherry CL, Bell JE, McLean CA: Brain Cell Reservoirs of
Latent Virus in Presymptomatic HIV-Infected Individuals. Am J Pathol
2011, 179:1623-1629.
56. Churchill MJ, Wesselingh SL, Cowley D, Pardo CA, McArthur JC, Brew BJ,
Gorry PR: Extensive astrocyte infection is prominent in human
immunodeficiency virus-associated dementia. Ann Neurol 2009,
66:253-258.
57. Vincendeau M, Kramer S, Hadian K, Rothenaigner I, Bell J, Hauck SM,
Bickel C, Nagel D, Kremmer E, Werner T, Leib-Mösch C, Brack-Werner R:
Control of HIV replication in astrocytes by a family of highly conserved
host proteins with a common Rev-interacting domain (Risp). AIDS 2010,
24:2433-2442.
58. Wang Z, Trillo-Pazos G, Kim SY, Canki M, Morgello S, Sharer LR, Gelbard HA,
Su ZZ, Kang DC, Brooks AI, Fisher PB, Volsky DJ: Effects of human
immunodeficiency virus type 1 on astrocyte gene expression and
function: potential role in neuropathogenesis. J Neurovirol 2004, 10(Suppl
1):25-32.
59. Kim SY, Li J, Bentsman G, Brooks AI, Volsky DJ: Microarray analysis of
changes in cellular gene expression induced by productive infection of
primary human astrocytes: implications for HAD. J Neuroimmunol 2004,
157:17-26.
60. Eugenin EA, Clements JE, Zink MC, Berman JW: Human immunodeficiency
virus infection of human astrocytes disrupts blood-brain barrier integrity
by a gap junction-dependent mechanism. J Neurosci 2011, 31:9456-9465.
61. Wang T, Gong N, Liu J, Kadiu I, Kraft-Terry SD, Schlautman JD, Ciborowski P,
Volsky DJ, Gendelman HE: HIV-1-infected astrocytes and the microglial
proteome. J Neuroimmune Pharmacol 2008, 3:173-186.
62. Radmark O, Samuelsson B: 5-Lipoxygenase: mechanisms of regulation. J
Lipid Res 2009, 50(Suppl):S40-45.
63. Borgeat P, Hamberg M, Samuelsson B: Transformation of arachidonic acid
and homo-gamma-linolenic acid by rabbit polymorphonuclear
leukocytes. Monohydroxy acids from novel lipoxygenases. J Biol Chem
1976, 251:7816-7820.
64. Radmark O, Malmsten C, Samuelsson B: Leukotriene A4: enzymatic
conversion to leukotriene C4. Biochem Biophys Res Commun 1980,
96:1679-1687.
65. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR:
Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of
constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993,
90:11693-11697.
66. Seibert K, Masferrer JL: Role of inducible cyclooxygenase (COX-2) in
inflammation. Receptor 1994, 4:17-23.
67. Botting R, Ayoub SS: COX-3 and the mechanism of action of
paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids 2005,
72:85-87.
68. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS,
Simmons DL: COX-3, a cyclooxygenase-1 variant inhibited by
acetaminophen and other analgesic/antipyretic drugs: cloning, structure,
and expression. Proc Natl Acad Sci USA 2002, 99:13926-13931.
69. Chandrasekharan NV, Simmons DL: The cyclooxygenases. Genome Biol
2004, 5:241.
70. Funk CD: Prostaglandins and leukotrienes: advances in eicosanoid
biology. Science 2001, 294:1871-1875.
71. Smith WL, DeWitt DL, Garavito RM: Cyclooxygenases: structural, cellular,
and molecular biology. Annu Rev Biochem 2000, 69:145-182.
72. Cha YI, Solnica-Krezel L, DuBois RN: Fishing for prostanoids: deciphering
the developmental functions of cyclooxygenase-derived prostaglandins.
Dev Biol 2006, 289:263-272.
73. Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C,
Kaidi A: The COX-2/PGE2 pathway: key roles in the hallmarks of cancer
and adaptation to the tumour microenvironment. Carcinogenesis 2009,
30:377-386.
74. Scher JU, Pillinger MH: The anti-inflammatory effects of prostaglandins. J
Investig Med 2009, 57:703-708.
75. Surh YJ, Na HK, Park JM, Lee HN, Kim W, Yoon IS, Kim DD: 15-Deoxy-Delta
(12,14)-prostaglandin J(2), an electrophilic lipid mediator of anti-
inflammatory and pro-resolving signaling. Biochem Pharmacol 2011,
82:1335-1351.
76. Samuelsson B: Leukotrienes: mediators of immediate hypersensitivity
reactions and inflammation. Science 1983, 220:568-575.
77. Peters-Golden M, Henderson WR Jr: Leukotrienes. N Engl J Med 2007,
357:1841-1854.
78. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ: Leukotrienes:
underappreciated mediators of innate immune responses. J Immunol
2005, 174:589-594.
79. Borgeat P, Samuelsson B: Arachidonic acid metabolism in
polymorphonuclear leukocytes: unstable intermediate in formation of
dihydroxy acids. Proc Natl Acad Sci USA 1979, 76:3213-3217.
Bertin et al. Retrovirology 2012, 9:4
http://www.retrovirology.com/content/9/1/4
Page 11 of 1480. Hopkins NK, Oglesby TD, Bundy GL, Gorman RR: Biosynthesis and
metabolism of 15-hydroperoxy-5,8,11,13-eicosatetraenoic acid by human
umbilical vein endothelial cells. J Biol Chem 1984, 259:14048-14053.
81. Humes JL, Opas EE, Galavage M, Soderman D, Bonney RJ: Regulation of
macrophage eicosanoid production by hydroperoxy-and hydroxy-
eicosatetraenoic acids. Biochem J 1986, 233:199-206.
82. Naruhn S, Meissner W, Adhikary T, Kaddatz K, Klein T, Watzer B, Muller-
Brusselbach S, Muller R: 15-hydroxyeicosatetraenoic acid is a preferential
peroxisome proliferator-activated receptor beta/delta agonist. Mol
Pharmacol 2010, 77:171-184.
83. Chen GG, Xu H, Lee JF, Subramaniam M, Leung KL, Wang SH, Chan UP,
Spelsberg TC: 15-hydroxy-eicosatetraenoic acid arrests growth of
colorectal cancer cells via a peroxisome proliferator-activated receptor
gamma-dependent pathway. Int J Cancer 2003, 107:837-843.
84. Paruchuri S, Hallberg B, Juhas M, Larsson C, Sjolander A: Leukotriene D(4)
activates MAPK through a Ras-independent but PKCepsilon-dependent
pathway in intestinal epithelial cells. J Cell Sci 2002, 115:1883-1893.
85. Sanchez-Galan E, Gomez-Hernandez A, Vidal C, Martin-Ventura JL, Blanco-
Colio LM, Munoz-Garcia B, Ortega L, Egido J, Tunon J: Leukotriene B4
enhances the activity of nuclear factor-kappaB pathway through BLT1
and BLT2 receptors in atherosclerosis. Cardiovasc Res 2009, 81:216-225.
86. Flamand N, Lefebvre J, Surette ME, Picard S, Borgeat P: Arachidonic acid
regulates the translocation of 5-lipoxygenase to the nuclear membranes
in human neutrophils. J Biol Chem 2006, 281:129-136.
87. Flamand N, Surette ME, Picard S, Bourgoin S, Borgeat P: Cyclic AMP-
mediated inhibition of 5-lipoxygenase translocation and leukotriene
biosynthesis in human neutrophils. Mol Pharmacol 2002, 62:250-256.
88. Singh RK, Gupta S, Dastidar S, Ray A: Cysteinyl leukotrienes and their
receptors: molecular and functional characteristics. Pharmacology 2010,
85:336-349.
89. Ciana P, Fumagalli M, Trincavelli ML, Verderio C, Rosa P, Lecca D, Ferrario S,
Parravicini C, Capra V, Gelosa P, Guerrini U, Belcredito S, Cimino M, Sironi L,
Tremoli E, Rovati GE, Martini C, Abbracchio MP: The orphan receptor
GPR17 identified as a new dual uracil nucleotides/cysteinyl-leukotrienes
receptor. Embo J 2006, 25:4615-4627.
90. Maekawa A, Balestrieri B, Austen KF, Kanaoka Y: GPR17 is a negative
regulator of the cysteinyl leukotriene 1 receptor response to leukotriene
D4. Proc Natl Acad Sci USA 2009, 106:11685-11690.
91. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD: Prostanoid receptors:
subtypes and signaling. Annu Rev Pharmacol Toxicol 2001, 41:661-690.
92. Scher JU, Pillinger MH: 15d-PGJ2: the anti-inflammatory prostaglandin?
Clin Immunol 2005, 114:100-109.
93. Yamamoto N, Harada S, Nakashima H: Substances affecting the infection
and replication of human immunodeficiency virus (HIV). AIDS Res 1986,
2(Suppl 1):S183-189.
94. Ankel H, Turriziani O, Antonelli G: Prostaglandin A inhibits replication of
human immunodeficiency virus during acute infection. J Gen Virol 1991,
72(Pt 11):2797-2800.
95. Hughes-Fulford M, McGrath MS, Hanks D, Erickson S, Pulliam L: Effects of
dimethyl prostaglandin A1 on herpes simplex virus and human
immunodeficiency virus replication. Antimicrob Agents Chemother 1992,
36:2253-2258.
96. Rozera C, Carattoli A, De Marco A, Amici C, Giorgi C, Santoro MG: Inhibition
of HIV-1 replication by cyclopentenone prostaglandins in acutely
infected human cells. Evidence for a transcriptional block. J Clin Invest
1996, 97:1795-1803.
97. Thivierge M, Le Gouill C, Tremblay MJ, Stankova J, Rola-Pleszczynski M:
Prostaglandin E2 induces resistance to human immunodeficiency virus-1
infection in monocyte-derived macrophages: downregulation of CCR5
expression by cyclic adenosine monophosphate. Blood 1998, 92:40-45.
98. Hayes MM, Lane BR, King SR, Markovitz DM, Coffey MJ: Prostaglandin E(2)
inhibits replication of HIV-1 in macrophages through activation of
protein kinase A. Cell Immunol 2002, 215:61-71.
99. Whitney JB, Asmal M, Geiben-Lynn R: Serpin induced antiviral activity of
prostaglandin synthetase-2 against HIV-1 replication. PLoS One 2011, 6:
e18589.
100. Dumais N, Barbeau B, Olivier M, Tremblay MJ: Prostaglandin E2 Up-
regulates HIV-1 long terminal repeat-driven gene activity in T cells via
NF-kappaB-dependent and -independent signaling pathways. J Biol
Chem 1998, 273:27306-27314.
101. Boisvert M, Cote S, Vargas A, Pasvanis S, Bounou S, Barbeau B, Dumais N:
PGJ2 antagonizes NF-kappaB-induced HIV-1 LTR activation in colonic
epithelial cells. Virology 2008, 380:1-11.
102. Kalantari P, Narayan V, Henderson AJ, Prabhu KS: 15-Deoxy-Delta12,14-
prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through
covalent modification. Faseb J 2009, 23:2366-2373.
103. Bailie MB, Standiford TJ, Laichalk LL, Coffey MJ, Strieter R, Peters-Golden M:
Leukotriene-deficient mice manifest enhanced lethality from Klebsiella
pneumonia in association with decreased alveolar macrophage
phagocytic and bactericidal activities. J Immunol 1996, 157:5221-5224.
104. Chen N, Restivo A, Reiss CS: Leukotrienes play protective roles early
during experimental VSV encephalitis. J Neuroimmunol 2001, 120:94-102.
105. Demitsu T, Katayama H, Saito-Taki T, Yaoita H, Nakano M: Enhanced
bactericidal activity of macrophages by exogenous leukotriene B4.
Dermatologica 1989, 179(Suppl 1):129-130.
106. Malaviya R, Abraham SN: Role of mast cell leukotrienes in neutrophil
recruitment and bacterial clearance in infectious peritonitis. J Leukoc Biol
2000, 67:841-846.
107. Medeiros AI, Sa-Nunes A, Soares EG, Peres CM, Silva CL, Faccioli LH:
Blockade of endogenous leukotrienes exacerbates pulmonary
histoplasmosis. Infect Immun 2004, 72:1637-1644.
108. Thorsen S, Busch-Sorensen M, Sondergaard J: Reduced neutrophil
production of leukotriene B4 associated with AIDS. Aids 1989, 3:651-653.
109. Coffey MJ, Phare SM, Kazanjian PH, Peters-Golden M: 5-Lipoxygenase
metabolism in alveolar macrophages from subjects infected with the
human immunodeficiency virus. J Immunol 1996, 157:393-399.
110. Coffey MJ, Phare SM, George S, Peters-Golden M, Kazanjian PH:
Granulocyte colony-stimulating factor administration to HIV-infected
subjects augments reduced leukotriene synthesis and anticryptococcal
activity in neutrophils. J Clin Invest 1998, 102:663-670.
111. Peters-Golden M, Coffey M: Role of leukotrienes in antimicrobial defense
of the lung. J Lab Clin Med 1998, 132:251-257.
112. Boudreau LH, Bertin J, Robichaud PP, Laflamme M, Ouellette RJ, Flamand N,
Surette ME: Novel 5-lipoxygenase isoforms affect the biosynthesis of 5-
lipoxygenase products. Faseb J 2011, 25:1097-1105.
113. Flamand L, Borgeat P, Lalonde R, Gosselin J: Release of anti-HIV mediators
after administration of leukotriene B4 to humans. J Infect Dis 2004,
189:2001-2009.
114. Flamand L, Tremblay MJ, Borgeat P: Leukotriene B4 triggers the in vitro
and in vivo release of potent antimicrobial agents. J Immunol 2007,
178:8036-8045.
115. Yao Q, Frank M, Glynn M, Altman RD: Rheumatic manifestations in HIV-1
infected in-patients and literature review. Clin Exp Rheumatol 2008,
26:799-806.
116. Cuellar ML: HIV infection-associated inflammatory musculoskeletal
disorders. Rheum Dis Clin North Am 1998, 24:403-421.
117. Berman A, Espinoza LR, Diaz JD, Aguilar JL, Rolando T, Vasey FB,
Germain BF, Lockey RF: Rheumatic manifestations of human
immunodeficiency virus infection. Am J Med 1988, 85:59-64.
118. Calabrese LH, Kelley DM, Myers A, O’Connell M, Easley K: Rheumatic
symptoms and human immunodeficiency virus infection. The influence
of clinical and laboratory variables in a longitudinal cohort study.
Arthritis Rheum 1991, 34:257-263.
119. Pereira CF, Paridaen JT, Rutten K, Huigen MC, van de Bovenkamp M,
Middel J, Beerens N, Berkhout B, Schuurman R, Marnett LJ, Verhoef J,
Nottet HS: Aspirin-like molecules that inhibit human immunodeficiency
virus 1 replication. Antiviral Res 2003, 58:253-263.
120. Pereira CF, Paridaen JT, van de Bovenkamp M, Middel J, Verhoef J,
Nottet HS: APHS can act synergically with clinically available HIV-1
reverse transcriptase and protease inhibitors and is active against
several drug-resistant HIV-1 strains in vitro. J Antimicrob Chemother 2003,
51:1181-1189.
121. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S, Otomo S: NS-398, a
new anti-inflammatory agent, selectively inhibits prostaglandin G/H
synthase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 1994,
47:55-59.
122. Pettersen FO, Torheim EA, Dahm AE, Aaberge IS, Lind A, Holm M,
Aandahl EM, Sandset PM, Tasken K, Kvale D: An exploratory trial of
cyclooxygenase type 2 inhibitor in HIV-1 infection: downregulated
immune activation and improved T cell-dependent vaccine responses. J
Virol 2011, 85:6557-6566.
Bertin et al. Retrovirology 2012, 9:4
http://www.retrovirology.com/content/9/1/4
Page 12 of 14123. Zhang D, Hu X, Qian L, Wilson B, Lee C, Flood P, Langenbach R, Hong JS:
Prostaglandin E2 released from activated microglia enhances astrocyte
proliferation in vitro. Toxicol Appl Pharmacol 2009, 238:64-70.
124. Rademacher DJ, Kearn CS, Carrier EJ, Patel S, Delgado MA, Barkmeier A,
Klick DE, Breese NM, Pfister SL, Nithipatikom K, Campbell WB, Hillard CJ:
Production of hydroxyeicosatetraenoic acids and prostaglandins by a
novel rat microglial cell line. J Neuroimmunol 2004, 149:130-141.
125. Matsuo M, Hamasaki Y, Fujiyama F, Miyazaki S: Eicosanoids are produced
by microglia, not by astrocytes, in rat glial cell cultures. Brain Res 1995,
685:201-204.
126. Ballerini P, Di Iorio P, Ciccarelli R, Caciagli F, Poli A, Beraudi A, Buccella S,
D’Alimonte I, D’Auro M, Nargi E, Patricelli P, Visini D, Traversa U: P2Y1 and
cysteinyl leukotriene receptors mediate purine and cysteinyl leukotriene
co-release in primary cultures of rat microglia. Int J Immunopathol
Pharmacol 2005, 18:255-268.
127. Minghetti L, Ajmone-Cat MA, De Berardinis MA, De Simone R: Microglial
activation in chronic neurodegenerative diseases: roles of apoptotic
neurons and chronic stimulation. Brain Res Brain Res Rev 2005, 48:251-256.
128. Choi SH, Aid S, Bosetti F: The distinct roles of cyclooxygenase-1 and -2 in
neuroinflammation: implications for translational research. Trends
Pharmacol Sci 2009, 30:174-181.
129. Lin TN, Wang Q, Simonyi A, Chen JJ, Cheung WM, He YY, Xu J, Sun AY,
Hsu CY, Sun GY: Induction of secretory phospholipase A2 in reactive
astrocytes in response to transient focal cerebral ischemia in the rat
brain. J Neurochem 2004, 90:637-645.
130. Bendani MK, Palluy O, Cook-Moreau J, Beneytout JL, Rigaud M, Vallat JM:
Localization of 12-lipoxygenase mRNA in cultured oligodendrocytes and
astrocytes by in situ reverse transcriptase and polymerase chain
reaction. Neurosci Lett 1995, 189:159-162.
131. Farooqui AA, Horrocks LA, Farooqui T: Modulation of inflammation in
brain: a matter of fat. J Neurochem 2007, 101:577-599.
132. Okubo M, Yamanaka H, Kobayashi K, Noguchi K: Leukotriene synthases
and the receptors induced by peripheral nerve injury in the spinal cord
contribute to the generation of neuropathic pain. Glia 2010, 58:599-610.
133. Jeon SB, Ji KA, You HJ, Kim JH, Jou I, Joe EH: Nordihydroguaiaretic acid
inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain
astrocytes. Biochem Biophys Res Commun 2005, 328:595-600.
134. Manev H, Uz T, Qu T: Early upregulation of hippocampal 5-lipoxygenase
following systemic administration of kainate to rats. Restor Neurol
Neurosci 1998, 12:81-85.
135. Tomimoto H, Shibata M, Ihara M, Akiguchi I, Ohtani R, Budka H: A
comparative study on the expression of cyclooxygenase and 5-
lipoxygenase during cerebral ischemia in humans. Acta Neuropathol 2002,
104:601-607.
136. Ohtsuki T, Matsumoto M, Hayashi Y, Yamamoto K, Kitagawa K, Ogawa S,
Yamamoto S, Kamada T: Reperfusion induces 5-lipoxygenase
translocation and leukotriene C4 production in ischemic brain. Am J
Physiol 1995, 268:H1249-1257.
137. Hoozemans JJ, Veerhuis R, Janssen I, van Elk EJ, Rozemuller AJ,
Eikelenboom P: The role of cyclo-oxygenase 1 and 2 activity in
prostaglandin E(2) secretion by cultured human adult microglia:
implications for Alzheimer’s disease. Brain Res 2002, 951:218-226.
138. Temel SG, Kahveci Z: Cyclooxygenase-2 expression in astrocytes and
microglia in human oligodendroglioma and astrocytoma. J Mol Histol
2009, 40:369-377.
139. Carlson NG, Rojas MA, Redd JW, Tang P, Wood B, Hill KE, Rose JW:
Cyclooxygenase-2 expression in oligodendrocytes increases sensitivity to
excitotoxic death. J Neuroinflammation 2010, 7:25.
140. Qin N, Zhang SP, Reitz TL, Mei JM, Flores CM: Cloning, expression, and
functional characterization of human cyclooxygenase-1 splicing variants:
evidence for intron 1 retention. J Pharmacol Exp Ther 2005, 315:1298-1305.
141. Andreasson K: Emerging roles of PGE2 receptors in models of
neurological disease. Prostaglandins Other Lipid Mediat 2010, 91:104-112.
142. Griffin DE, Wesselingh SL, McArthur JC: Elevated central nervous system
prostaglandins in human immunodeficiency virus-associated dementia.
Ann Neurol 1994, 35:592-597.
143. Heise CE, O’Dowd BF, Figueroa DJ, Sawyer N, Nguyen T, Im DS, Stocco R,
Bellefeuille JN, Abramovitz M, Cheng R, Williams DL Jr, Zeng Z, Liu Q, Ma L,
Clements MK, Coulombe N, Liu Y, Austin CP, George SR, O’Neill GP,
Metters KM, Lynch KR, Evans JF: Characterization of the human cysteinyl
leukotriene 2 receptor. J Biol Chem 2000, 275:30531-30536.
144. Hu H, Chen G, Zhang JM, Zhang WP, Zhang L, Ge QF, Yao HT, Ding W,
Chen Z, Wei EQ: Distribution of cysteinyl leukotriene receptor 2 in
human traumatic brain injury and brain tumors. Acta Pharmacol Sin 2005,
26:685-690.
145. Lecca D, Trincavelli ML, Gelosa P, Sironi L, Ciana P, Fumagalli M, Villa G,
Verderio C, Grumelli C, Guerrini U, Tremoli E, Rosa P, Cuboni S, Martini C,
Buffo A, Cimino M, Abbracchio MP: The recently identified P2Y-like
receptor GPR17 is a sensor of brain damage and a new target for brain
repair. PLoS One 2008, 3:e3579.
146. Hui Y, Funk CD: Cysteinyl leukotriene receptors. Biochem Pharmacol 2002,
64:1549-1557.
147. Di Gennaro A, Carnini C, Buccellati C, Ballerio R, Zarini S, Fumagalli F,
Viappiani S, Librizzi L, Hernandez A, Murphy RC, Constantin G, De Curtis M,
Folco G, Sala A: Cysteinyl-leukotrienes receptor activation in brain
inflammatory reactions and cerebral edema formation: a role for
transcellular biosynthesis of cysteinyl-leukotrienes. Faseb J 2004,
18:842-844.
148. Zhang WP, Hu H, Zhang L, Ding W, Yao HT, Chen KD, Sheng WW, Chen Z,
Wei EQ: Expression of cysteinyl leukotriene receptor 1 in human
traumatic brain injury and brain tumors. Neurosci Lett 2004, 363:247-251.
149. Froldi M, Castagna A, Parma M, Piona A, Tedeschi A, Miadonna A, Lorini M,
Orazio EN, Lazzarin A: Mediator release in cerebrospinal fluid of human
immunodeficiency virus-positive patients with central nervous system
involvement. J Neuroimmunol 1992, 38:155-161.
150. Pereira CF, Boven LA, Middel J, Verhoef J, Nottet HS: Induction of
cyclooxygenase-2 expression during HIV-1-infected monocyte-derived
macrophage and human brain microvascular endothelial cell
interactions. J Leukoc Biol 2000, 68:423-428.
151. Alvarez S, Serramia MJ, Fresno M, Munoz-Fernandez M: Human
immunodeficiency virus type 1 envelope glycoprotein 120 induces
cyclooxygenase-2 expression in neuroblastoma cells through a nuclear
factor-kappaB and activating protein-1 mediated mechanism. J
Neurochem 2005, 94:850-861.
152. Alvarez S, Serramia MJ, Fresno M, Munoz-Fernandez MA: HIV-1 envelope
glycoprotein 120 induces cyclooxygenase-2 expression in astrocytoma
cells through a nuclear factor-kappaB-dependent mechanism.
Neuromolecular Med 2007, 9:179-193.
153. Gray F, Adle-Biassette H, Brion F, Ereau T, le Maner I, Levy V, Corcket G:
Neuronal apoptosis in human immunodeficiency virus infection. J
Neurovirol 2000, 6(Suppl 1):S38-43.
154. Gray F, Adle-Biassette H, Chretien F, Lorin de la Grandmaison G, Force G,
Keohane C: Neuropathology and neurodegeneration in human
immunodeficiency virus infection. Pathogenesis of HIV-induced lesions
of the brain, correlations with HIV-associated disorders and
modifications according to treatments. Clin Neuropathol 2001, 20:146-155.
155. Bansal AK, Mactutus CF, Nath A, Maragos W, Hauser KF, Booze RM:
Neurotoxicity of HIV-1 proteins gp120 and Tat in the rat striatum. Brain
Res 2000, 879:42-49.
156. Louboutin JP, Reyes BA, Agrawal L, Van Bockstaele EJ, Strayer DS: HIV-1
gp120-induced neuroinflammation: relationship to neuron loss and
protection by rSV40-delivered antioxidant enzymes. Exp Neurol 2010,
221:231-245.
157. Kaul M, Lipton SA: Chemokines and activated macrophages in HIV
gp120-induced neuronal apoptosis. Proc Natl Acad Sci USA 1999,
96:8212-8216.
158. Medders KE, Sejbuk NE, Maung R, Desai MK, Kaul M: Activation of p38
MAPK is required in monocytic and neuronal cells for HIV glycoprotein
120-induced neurotoxicity. J Immunol 2010, 185:4883-4895.
159. Corasaniti MT, Rotiroti D, Nappi G, Bagetta G: Neurobiological mediators of
neuronal apoptosis in experimental neuroAIDS. Toxicol Lett 2003,
139:199-206.
160. Bagetta G, Corasaniti MT, Paoletti AM, Berliocchi L, Nistico R,
Giammarioli AM, Malorni W, Finazzi-Agro A: HIV-1 gp120-induced
apoptosis in the rat neocortex involves enhanced expression of cyclo-
oxygenase type 2 (COX-2). Biochem Biophys Res Commun 1998,
244:819-824.
161. Maccarrone M, Bari M, Corasaniti MT, Nistico R, Bagetta G, Finazzi-Agro A:
HIV-1 coat glycoprotein gp120 induces apoptosis in rat brain neocortex
by deranging the arachidonate cascade in favor of prostanoids. J
Neurochem 2000, 75:196-203.
Bertin et al. Retrovirology 2012, 9:4
http://www.retrovirology.com/content/9/1/4
Page 13 of 14162. Samikkannu T, Agudelo M, Gandhi N, Reddy PV, Saiyed ZM, Nwankwo D,
Nair MP: Human immunodeficiency virus type 1 clade B and C gp120
differentially induce neurotoxin arachidonic acid in human astrocytes:
implications for neuroAIDS. J Neurovirol 2011, 17:230-238.
163. Corasaniti MT, Turano P, Bilotta A, Malorni W, Stringaro AR, Nistico R,
Finazzi-Agro A, Bagetta G: Evidence that increases of mitochondrial
immunoreactive IL-1beta by HIV-1 gp120 implicate in situ cleavage of
pro-IL-1beta in the neocortex of rat. J Neurochem 2001, 78:611-618.
164. Corasaniti MT, Bilotta A, Strongoli MC, Navarra M, Bagetta G, Di Renzo G:
HIV-1 coat protein gp120 stimulates interleukin-1beta secretion from
human neuroblastoma cells: evidence for a role in the mechanism of
cell death. Br J Pharmacol 2001, 134:1344-1350.
165. Pu H, Hayashi K, Andras IE, Eum SY, Hennig B, Toborek M: Limited role of
COX-2 in HIV Tat-induced alterations of tight junction protein expression
and disruption of the blood-brain barrier. Brain Res 2007, 1184:333-344.
166. Blanco A, Alvarez S, Fresno M, Munoz-Fernandez MA: Extracellular HIV-Tat
induces cyclooxygenase-2 in glial cells through activation of nuclear
factor of activated T cells. J Immunol 2008, 180:530-540.
167. Flora G, Pu H, Hennig B, Toborek M: Cyclooxygenase-2 is involved in HIV-
1 Tat-induced inflammatory responses in the brain. Neuromolecular Med
2006, 8:337-352.
168. Wahl LM, Corcoran ML, Pyle SW, Arthur LO, Harel-Bellan A, Farrar WL:
Human immunodeficiency virus glycoprotein (gp120) induction of
monocyte arachidonic acid metabolites and interleukin 1. Proc Natl Acad
Sci USA 1989, 86:621-625.
169. Basselin M, Ramadan E, Igarashi M, Chang L, Chen M, Kraft AD, Harry GJ,
Rapoport SI: Imaging upregulated brain arachidonic acid metabolism in
HIV-1 transgenic rats. J Cereb Blood Flow Metab 2011, 31:486-493.
170. Rao JS, Kim HW, Kellom M, Greenstein D, Chen M, Kraft AD, Harry GJ,
Rapoport SI, Basselin M: Increased neuroinflammatory and arachidonic
acid cascade markers, and reduced synaptic proteins, in brain of HIV-1
transgenic rats. J Neuroinflammation 2011, 8:101.
171. Genis P, Jett M, Bernton EW, Boyle T, Gelbard HA, Dzenko K, Keane RW,
Resnick L, Mizrachi Y, Volsky DJ, Epstein LG, Gendelman HE: Cytokines and
arachidonic metabolites produced during human immunodeficiency
virus (HIV)-infected macrophage-astroglia interactions: implications for
the neuropathogenesis of HIV disease. J Exp Med 1992, 176:1703-1718.
172. Maccarrone M, Navarra M, Corasaniti MT, Nistico G, Finazzi Agro A:
Cytotoxic effect of HIV-1 coat glycoprotein gp120 on human
neuroblastoma CHP100 cells involves activation of the arachidonate
cascade. Biochem J 1998, 333(Pt 1):45-49.
173. Niknami M, Patel M, Witting PK, Dong Q: Molecules in focus: cytosolic
phospholipase A2-alpha. Int J Biochem Cell Biol 2009, 41:994-997.
doi:10.1186/1742-4690-9-4
Cite this article as: Bertin et al.: Interactions between prostaglandins,
leukotrienes and HIV-1: Possible implications for the central nervous
system. Retrovirology 2012 9:4.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bertin et al. Retrovirology 2012, 9:4
http://www.retrovirology.com/content/9/1/4
Page 14 of 14